NCT00989469 2026-02-05
NEXIRI
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
Clinical Trials
41 trialsNCT03211416 2026-02-05
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01754987 2025-05-04
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
Phase 1/2 Completed
NCT02279719 2023-11-15
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT00634634 2023-11-09
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Completed
NCT02728050 2023-07-05
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
University of Washington
Phase 1/2 Completed
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT00392821 2022-06-06
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT01434602 2022-06-01
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01271504 2021-05-12
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
Eisai Inc.
Phase 1/2 Completed
NCT00121251 2021-04-06
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01445080 2021-02-02
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01264705 2020-11-12
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT00892424 2020-09-10
Sorafenib-RT Treatment for Liver Metastasis (SLIM)
University Health Network, Toronto
Phase 1/2 Completed
NCT02560779 2020-07-17
Trial of TRC105 and Sorafenib in Patients With HCC
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02530476 2020-03-31
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00565370 2020-01-18
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP
Asan Medical Center
Phase 1/2 Completed
NCT00634751 2019-11-26
CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma
University of Wisconsin, Madison
Phase 1/2 Completed
NCT00474929 2019-08-20
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00869570 2019-05-15
External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer
Swiss Cancer Institute
Phase 1/2 Completed
NCT01306058 2019-01-23
Sorafenib and TRC105 in Hepatocellular Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01534260 2018-08-17
Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype
Indiana University
Phase 1/2 Completed
NCT00335764 2018-07-02
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00828074 2017-02-27
Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT00785226 2016-10-17
RDEA119 and Sorafenib Combination Dose Escalation Study
Bayer
Phase 1/2 Completed
NCT01254890 2016-05-06
Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00448149 2016-03-17
Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT00712790 2016-01-06
Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)
Singapore Clinical Research Institute
Phase 1/2 Completed
NCT00609934 2015-07-23
Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone
University Health Network, Toronto
Phase 1/2 Completed
NCT00825734 2014-12-22
Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00815295 2014-12-08
Study of Sorafenib/Cetuximab in Head and Neck Cancer
Duke University
Phase 1/2 Completed
NCT00217399 2014-05-28
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00414388 2014-04-07
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
Oncology Specialists, S.C.
Phase 1/2 Completed
NCT00864032 2013-04-10
Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall
University of California, Davis
Phase 1/2 Completed
NCT00536575 2013-02-27
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00882869 2011-07-13
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Aegera Therapeutics
Phase 1/2 Completed
NCT00933816 2010-11-25
SILIUS
Kindai University
Phase 1/2 Completed
NCT00768937 2010-11-09
Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma
Medical University of Vienna
Phase 1/2 Completed
NCT00389285 2009-05-27
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
ZymoGenetics
Phase 1/2 Completed